Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc. - Common Stock
(NQ:
DNLI
)
20.79
+0.26 (+1.25%)
Delayed Quote
Updated: 9:32 AM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
18,654
Open
20.85
Bid (Size)
20.60 (400)
Ask (Size)
20.97 (200)
Prev. Close
20.53
Today's Range
20.79 - 20.85
52wk Range
13.75 - 27.30
Shares Outstanding
121,640,069
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
September 30, 2026
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END
Via
FinancialNewsMedia
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
AVLAYAH revenue hit $3.6M in first full quarter post-approval.
Via
The Motley Fool
Topics
Earnings
Performance
YTD
+27.8%
+27.8%
1 Month
-10.7%
-10.7%
3 Month
-19.5%
-19.5%
6 Month
+0.7%
+0.7%
1 Year
+39.4%
+39.4%
More News
Read More
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout
↗
August 12, 2026
Via
Chartmill
Denali Therapeutics Q2 Earnings Call Highlights
↗
August 06, 2026
Via
MarketBeat
Topics
Earnings
Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates
↗
August 06, 2026
Via
Chartmill
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 06, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
July 27, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
July 09, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
June 18, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 21, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
↗
May 18, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
↗
May 16, 2026
Via
MarketBeat
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 07, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
↗
May 05, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
April 20, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
From
BioMedWire
Via
GlobeNewswire
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
April 03, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 25, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
From
BioMedWire
Via
GlobeNewswire
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via
MarketMinute
Topics
Intellectual Property
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 05, 2026
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Denali Therapeutics Inc. - Common Stock publicly traded?
Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Denali Therapeutics Inc. - Common Stock trade on?
Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 20.79
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 10/02/26 09:32 AM ET
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 2.53B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
